Lakefront Biotherapeutics (GLPGF) Current Leases (2017 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Current Leases for 9 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Current Leases fell 42.59% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 42.59% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 48.12% from the prior year.
• Current Leases was $1.9 million for Q1 2026 at Lakefront Biotherapeutics, down from $2.0 million in the prior quarter.
• Over five years, Current Leases peaked at $7.9 million in Q1 2022 and troughed at $1.9 million in Q1 2026.
• A 5-year average of $4.4 million and a median of $4.5 million in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases declined 10.75% in 2022 and plunged 56.21% in 2025, its largest moves.
• Over 5 years, Current Leases stood at $7.4 million in 2022, then plunged by 31.95% to $5.0 million in 2023, then decreased by 25.73% to $3.7 million in 2024, then tumbled by 45.86% to $2.0 million in 2025, then fell by 7.86% to $1.9 million in 2026.
• The last three Current Leases figures came in at $1.9 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.